Suppr超能文献

靶向溶酶体:非酒精性脂肪性肝病的机制与治疗。

Targeting the lysosome: Mechanisms and treatments for nonalcoholic fatty liver disease.

机构信息

Department of Molecular Genetics and Microbiology, Autophagy, Inflammation, and Metabolism (AIM) Center of Biomedical Research Excellence, University of New Mexico, Albuquerque, New Mexico, USA.

出版信息

J Cell Biochem. 2022 Oct;123(10):1624-1633. doi: 10.1002/jcb.30274. Epub 2022 May 23.

Abstract

The multiple functions of the lysosome, including degradation, nutrient sensing, signaling, and gene regulation, enable the lysosome to regulate lipid metabolism at different levels. In this review, I summarize the recent studies on lysosomal regulation of lipid metabolism and the alterations of the lysosome functions in the livers affected by nonalcoholic fatty liver disease (NAFLD). NAFLD is a highly prevalent lipid metabolic disorder. The progression of NAFLD leads to nonalcoholic steatohepatitis (NASH) and other severe liver diseases, and thus the prevention and treatments of NAFLD progression are critically needed. Targeting the lysosome is a promising strategy. I also discuss the current manipulations of the lysosome functions in the preclinical studies of NAFLD and propose my perspectives on potential future directions.

摘要

溶酶体具有多种功能,包括降解、营养感应、信号转导和基因调控,使其能够在不同层面上调节脂质代谢。在这篇综述中,我总结了最近关于溶酶体调节脂质代谢的研究,以及非酒精性脂肪性肝病 (NAFLD) 影响的肝脏中溶酶体功能的改变。NAFLD 是一种高发的脂质代谢紊乱。NAFLD 的进展会导致非酒精性脂肪性肝炎 (NASH) 和其他严重的肝脏疾病,因此迫切需要预防和治疗 NAFLD 的进展。靶向溶酶体是一种很有前途的策略。我还讨论了目前在 NAFLD 的临床前研究中对溶酶体功能的操作,并对潜在的未来方向提出了我的看法。

相似文献

1
Targeting the lysosome: Mechanisms and treatments for nonalcoholic fatty liver disease.
J Cell Biochem. 2022 Oct;123(10):1624-1633. doi: 10.1002/jcb.30274. Epub 2022 May 23.
2
The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Mol Aspects Med. 2017 Aug;56:34-44. doi: 10.1016/j.mam.2017.04.004. Epub 2017 May 5.
3
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
Transplantation. 2019 Jan;103(1):e1-e13. doi: 10.1097/TP.0000000000002480.
4
Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Free Radic Biol Med. 2017 Oct;111:173-185. doi: 10.1016/j.freeradbiomed.2017.01.023. Epub 2017 Jan 18.
6
Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Exp Mol Med. 2023 Jul;55(7):1520-1530. doi: 10.1038/s12276-023-01036-7. Epub 2023 Jul 3.
7
Recent updates on targeting the molecular mediators of NAFLD.
J Mol Med (Berl). 2023 Feb;101(1-2):101-124. doi: 10.1007/s00109-022-02282-4. Epub 2023 Feb 16.
8
Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances.
Prog Lipid Res. 2023 Jul;91:101238. doi: 10.1016/j.plipres.2023.101238. Epub 2023 May 25.
9
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G462-G472. doi: 10.1152/ajpgi.00358.2018. Epub 2019 Jan 17.
10
Lipid mediators of liver injury in nonalcoholic fatty liver disease.
Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G75-G81. doi: 10.1152/ajpgi.00170.2018. Epub 2018 Nov 1.

本文引用的文献

1
Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD.
Hepatology. 2022 Nov;76(5):1452-1465. doi: 10.1002/hep.32324. Epub 2022 Apr 14.
2
CRISPR screens for lipid regulators reveal a role for ER-bound SNX13 in lysosomal cholesterol export.
J Cell Biol. 2022 Feb 7;221(2). doi: 10.1083/jcb.202105060. Epub 2021 Dec 22.
3
The roles of autophagy and thyroid hormone in the pathogenesis and treatment of NAFLD.
Hepatoma Res. 2021 Nov 5;7:72. doi: 10.20517/2394-5079.2021.82. eCollection 2021.
4
Lipid-induced DRAM recruits STOM to lysosomes and induces LMP to promote exosome release from hepatocytes in NAFLD.
Sci Adv. 2021 Nov 5;7(45):eabh1541. doi: 10.1126/sciadv.abh1541. Epub 2021 Nov 3.
5
Hepatic lysosomal acid lipase overexpression worsens hepatic inflammation in mice fed a Western diet.
J Lipid Res. 2021;62:100133. doi: 10.1016/j.jlr.2021.100133. Epub 2021 Oct 5.
6
Autophagy in metabolic disease and ageing.
Nat Rev Endocrinol. 2021 Nov;17(11):647-661. doi: 10.1038/s41574-021-00551-9. Epub 2021 Sep 10.
7
Lipotoxicity-induced STING1 activation stimulates MTORC1 and restricts hepatic lipophagy.
Autophagy. 2022 Apr;18(4):860-876. doi: 10.1080/15548627.2021.1961072. Epub 2021 Aug 12.
9
SREBP-1c impairs ULK1 sulfhydration-mediated autophagic flux to promote hepatic steatosis in high-fat-diet-fed mice.
Mol Cell. 2021 Sep 16;81(18):3820-3832.e7. doi: 10.1016/j.molcel.2021.06.003. Epub 2021 Jul 6.
10
Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway.
Front Pharmacol. 2021 May 17;12:589273. doi: 10.3389/fphar.2021.589273. eCollection 2021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验